Obstructive Sleep Apnea News and Research

RSS

Obstructive sleep apnea (OSA) is a major heath problem. In the United States, at least 17 million people have moderate to severe OSA, which is characterized by heavy snoring, airway blockage and frequent awakenings during sleep.

CPAP therapy effective at recouping memory abilities impaired by obstructive sleep apnea

Continuous positive airway pressure therapy helps restore memory consolidation in adults with obstructive sleep apnea, suggests a research abstract that will be presented Wednesday, June 9, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

9 Jun 2010

Phase 2 study results of Qnexa in patients with OSA presented at SLEEP 2010

VIVUS, Inc. today announced that data from a previously reported phase 2 study evaluating the safety and efficacy of the investigational drug Qnexa for the treatment of obstructive sleep apnea were presented at SLEEP 2010, the 24th Annual Meeting of the Associated Professional Sleep Societies.

8 Jun 2010

Children and teens with moderate to severe OSA have lower academic grades: Research

The average academic grades of children and teens with moderate to severe obstructive sleep apnea are worse than the grades of students who have no sleep-disordered breathing, according to a research abstract that will be presented Tuesday, June 8, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

8 Jun 2010

Excessive sleepiness more common in the U.S. than in Europe: Research

Excessive sleepiness is more common in the U.S. than in Europe, which raises concerns for public health and safety, according to a research abstract that will be presented Tuesday, June 8, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

8 Jun 2010

Watermark Medical completes $15M equity investment from CA Technologies

Watermark Medical, Inc., a privately-held medical products and services company currently servicing the sleep-disordered breathing market, today announced the completion of a $15 million equity investment from CA Technologies. This equity investment in Watermark Medical represents CA Technologies' entry into the emerging Software-as-a-Service -based healthcare cloud market.

7 Jun 2010

Positive results from VIVUS' Phase 3 study of avanafil for ED in men with diabetes

VIVUS, Inc. today announced positive results from the phase 3 REVIVE-Diabetes (TA-302) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED) in men with type 1 and type 2 diabetes. The REVIVE-Diabetes study met all three primary endpoints across the two doses studied by demonstrating statistically significant improvement in erectile function as measured by the Sexual Encounter Profile (SEP) and improvements in the International Index of Erectile Function (IIEF) score.

7 Jun 2010

Seasonal allergies may cause mild sleep-disordered breathing in young children: Research

The prevalence of mild sleep-disordered breathing in young children may fluctuate seasonally, suggests a research abstract that will be presented Monday, June 7, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

7 Jun 2010

CPAP Therapy increases gray-matter volume in obstructive sleep apnea patients

Obstructive sleep apnea patients had reductions of grey-matter volume at baseline but showed significant grey-matter volume increase after three months of CPAP therapy, according to a research abstract that will be presented Monday, June 7, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

7 Jun 2010

Sleep apnea treatment remains effective between 31 and 53 months after beginning oral appliance therapy

According to new research that will be presented on Saturday, June 5, at the 19th Annual Meeting of the American Academy of Dental Sleep Medicine, between 31 and 53 months after beginning oral appliance therapy, the sleep apnea treatment remained effective. Subjective daytime sleepiness, fatigue severity, and quality of life also remained improved.

5 Jun 2010

Researchers assess influence of oral dimensions on MAS treatment success in patients with OSA

According to new research that will receive the Graduate Student Research Award on Saturday, June 5, at the 19th Annual Meeting of the American Academy of Dental Sleep Medicine, the ratio between tongue volume and bony enclosure size in patients with obstructive sleep apnea may help dentists calculate oral appliance treatment success.

5 Jun 2010

US dental school graduates not adequately prepared to screen for sleep disorders

According to new research that will be presented on Saturday, June 5, at the 19th Annual Meeting of the American Academy of Dental Sleep Medicine, the majority of U.S. dental schools have not adequately prepared their graduates to screen for sleep disorders, which affect more than 70 million adults in the U.S.

5 Jun 2010

Study finds 18% of pediatric patients at-risk for sleep-related breathing disorders

According to new research that will be presented on Saturday, June 5, at the 19th Annual Meeting of the American Academy of Dental Sleep Medicine, an estimated 18 percent of pediatric patients in a University of North Carolina-based study were at-risk for sleep-related breathing disorders (SRBD). Importantly, pediatric risk was not associated with any demographic or craniofacial characteristics, as it is in adults, making it difficult to detect.

5 Jun 2010

Nasendoscopies help predict response to OAT in sleep apnea patients

According to new research that will be presented on Saturday, June 5, at the 19th Annual Meeting of the American Academy of Dental Sleep Medicine, nasendoscopy may help dentists predict oral appliance therapy success in sleep apnea patients. Nasendoscopy involves a flexible endoscope being inserted through the nasal cavity. The tip of the scope is placed at the level of the velopharynx and oro-/hypopharynx.

5 Jun 2010

New research: Questionnaires can help dentists screen for SDB in pediatric population

According to new research that will receive the Graduate Student Research Award on Saturday, June 5, at the 19th Annual Meeting of the American Academy of Dental Sleep Medicine, questionnaires can help dentists screen for sleep-disordered breathing in a pediatric population. SDB includes obstructive sleep apnea, upper-airway resistance syndrome, and snoring.

5 Jun 2010

Phase II trial of NUVIGIL Tablets for treatment of schizophrenia fails to meet primary endpoint: Cephalon

Cephalon, Inc. today announced that the primary endpoint was not met in a Phase II clinical trial that examined NUVIGIL (armodafinil) Tablets [C-IV] as an adjunctive therapy for the treatment of the negative symptoms of schizophrenia, which include problems with motivation and emotional withdrawal.

3 Jun 2010

Phase 3 pivotal REVIVE study data of VIVUS' avanafil for ED presented at 2010 AUA

VIVUS, Inc. today announced that data from the previously reported phase 3 pivotal REVIVE (TA-301) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED), were presented at the American Urological Association (AUA) 2010 Annual Meeting.

2 Jun 2010

VIVUS to present phase 3 data on avanafil for treatment of ED at AUA 2010

VIVUS, Inc. today announced that phase 3 data on avanafil, a next generation oral phosphodiesterase type 5 inhibitor therapy being investigated for the treatment of erectile dysfunction, will be presented next Tuesday at the American Urological Association 2010 Annual Meeting in San Francisco, California.

28 May 2010

Studies show positive effects of CPAP on cardiovascular incidence in non-sleepy OSA patients

In non-sleepy patients with obstructive sleep apnea, treatment with continuous positive airway pressure can reduce the incidence of cardiovascular events and hypertension, according to researchers from Spain.

20 May 2010

Home portable monitor testing can be used to diagnose, manage patients with OSA: Study

Patients with suspected obstructive sleep apnea may no longer have to spend an expensive and uncomfortable night at a sleep center to monitor their sleep-disordered breathing. According to new research, those who performed sleep testing in their home with portable monitors showed similar improvements after three months of treatment with continuous positive airway pressure in daytime function as compared to patients who underwent overnight testing in a sleep center.

20 May 2010

Apnex HGNS System shows promising results in people suffering from OSA

Apnex Medical announced today that preliminary data from a first-in-man clinical study showed significant improvements in sleep for people suffering from obstructive sleep apnea. The Apnex HGNS™ System, developed by the St. Paul-based company, is a device designed to treat OSA, which is a serious life-threatening illness characterized by fragmented sleep and excessive day-time sleepiness.

18 May 2010

Obstructive Sleep Apnea News and Research

Further Reading

CPAP therapy effective at recouping memory abilities impaired by obstructive sleep apnea

Phase 2 study results of Qnexa in patients with OSA presented at SLEEP 2010

Children and teens with moderate to severe OSA have lower academic grades: Research

Excessive sleepiness more common in the U.S. than in Europe: Research

Watermark Medical completes $15M equity investment from CA Technologies

Positive results from VIVUS' Phase 3 study of avanafil for ED in men with diabetes

Seasonal allergies may cause mild sleep-disordered breathing in young children: Research

CPAP Therapy increases gray-matter volume in obstructive sleep apnea patients

Sleep apnea treatment remains effective between 31 and 53 months after beginning oral appliance therapy

Researchers assess influence of oral dimensions on MAS treatment success in patients with OSA

US dental school graduates not adequately prepared to screen for sleep disorders

Study finds 18% of pediatric patients at-risk for sleep-related breathing disorders

Nasendoscopies help predict response to OAT in sleep apnea patients

New research: Questionnaires can help dentists screen for SDB in pediatric population

Phase II trial of NUVIGIL Tablets for treatment of schizophrenia fails to meet primary endpoint: Cephalon

Phase 3 pivotal REVIVE study data of VIVUS' avanafil for ED presented at 2010 AUA

VIVUS to present phase 3 data on avanafil for treatment of ED at AUA 2010

Studies show positive effects of CPAP on cardiovascular incidence in non-sleepy OSA patients

Home portable monitor testing can be used to diagnose, manage patients with OSA: Study

Apnex HGNS System shows promising results in people suffering from OSA

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News